Pomer krátenia spoločnosti Adma Biologics Inc
Aká je hodnota metriky Pomer krátenia spoločnosti Adma Biologics Inc?
Hodnota metriky Pomer krátenia spoločnosti Adma Biologics Inc je 7.56
Aká je definícia metriky Pomer krátenia?
Pomer krátenia (Short ratio) je pomer akcií predaných na krátko a priemerným denným objemom.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Pomer krátenia spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adma Biologics Inc
Čomu sa venuje spoločnosť Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Firmy s metrikou pomer krátenia podobnou spoločnosti Adma Biologics Inc
- Hodnota metriky Pomer krátenia spoločnosti Switch Inc je 7.54
- Hodnota metriky Pomer krátenia spoločnosti MVB je 7.54
- Hodnota metriky Pomer krátenia spoločnosti Stride Inc je 7.54
- Hodnota metriky Pomer krátenia spoločnosti Azure Power Global Ltd je 7.55
- Hodnota metriky Pomer krátenia spoločnosti Signet Jewelers Ltd je 7.55
- Hodnota metriky Pomer krátenia spoločnosti First Foundation Inc je 7.55
- Hodnota metriky Pomer krátenia spoločnosti Adma Biologics Inc je 7.56
- Hodnota metriky Pomer krátenia spoločnosti Organogenesis je 7.57
- Hodnota metriky Pomer krátenia spoločnosti ViewRay je 7.57
- Hodnota metriky Pomer krátenia spoločnosti Syncora je 7.57
- Hodnota metriky Pomer krátenia spoločnosti Nikola je 7.58
- Hodnota metriky Pomer krátenia spoločnosti Hylands International je 7.58
- Hodnota metriky Pomer krátenia spoločnosti Nicolet Bankshares je 7.58